Table 4.
Individual TDR mutations
| NRTI | N (%) | NNRTI | N (%) | PI | N(%) | |||
|---|---|---|---|---|---|---|---|---|
| Any | 75 (4.0) | Any | 85 (4.5) | Any | 52 (2.8) | |||
| M41 | L | 28 (1.5) | L100 | I | 0 (0.0) | L23 | I | 0 (0.0) |
| K65 | R | 0 (0.0) | K101 | EP | 4 (0.2) | L24 | I | 1 (0.1) |
| D67 | NGE | 12 (0.6) | K103 | NS*** | 53 (2.8) | D30 | N | 3 (0.2) |
| T69 | D, Ins* | 3 (0.2) | V106 | MA | 2 (0.1) | V32 | I | 0 (0.0) |
| K70 | RE | 6 (0.3) | E138 | K | 5 (0.3) | M46 | IL | 22 (1.2) |
| L74 | VI | 0 (0.0) | V179 | F | 0 (0.0) | I47 | VA | 2 (0.1) |
| V75 | MTAS | 0 (0.0) | Y181 | CIV | 9 (0.5) | G48 | VM | 0 (0.0) |
| F77 | L | 4 (0.2) | Y188 | LHC | 5 (0.3) | I50 | VL | 1 (0.1) |
| Y115 | F | 0 (0.0) | G190 | ASE | 13 (0.7) | F53 | LY | 4 (0.2) |
| F116 | Y | 0 (0.0) | P225 | H | 1 (0.1) | I54 | VLMATS | 6 (0.3) |
| Q151 | M | 0 (0.0) | M230 | L | 1 (0.1) | G73 | STCA | 5 (0.3) |
| M184 | VI | 0 (0.0) | L76 | V | 1 (0.1) | |||
| L210 | W | 8 (0.4) | V82 | ATFSCML | 7 (0.4) | |||
| T215 | YFISCDVEN** | 51 (2.7) | N83 | D | 0 (0.0) | |||
| K219 | QENR | 16 (0.9) | I84 | VAC | 2 (0.1) | |||
| I85 | V | 3 (0.2) | ||||||
| N88 | DS | 2 (0.1) | ||||||
| L90 | M | 13 (0.7) | ||||||
Participants may have more than 1 mutation within each class, similarly they may have mutations for more than 1 class.
Based on 1869 participants from United States, Europe, Australia and Asia.
TDR defined according to WHO classification (2009) & E138K and T215N
*
1 participant had an insertion at position 69
**
2 participants had T215F, and 3 patients with T215Y mutations, 0 participants with T215N
***
7 participants had a K103S mutation.
TDR=transmitted drug resistance; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non- nucleoside reverse transcriptase inhibitor; PI=protease inhibitor.